10x Genomics, Inc. (TXG)
Largest Insider Buys in Sector
TXG Stock Price History Chart
TXG Stock Performance
About 10x Genomics, Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for …
Insider Activity of 10x Genomics, Inc.
Over the last 12 months, insiders at 10x Genomics, Inc. have bought $0 and sold $1.8M worth of 10x Genomics, Inc. stock.
On average, over the past 5 years, insiders at 10x Genomics, Inc. have bought $12,793 and sold $283.6M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 158 shares for transaction amount of $6,397 was made by McAnear Justin J. (Chief Financial Officer) on 2022‑05‑13.
List of Insider Buy and Sell Transactions, 10x Genomics, Inc.
| 2024-11-22 | Sale | Chief Executive Officer | 6,693 0.0052% | $13.69 | $91,612 | +8.18% | ||
| 2024-11-22 | Sale | See Remarks | 5,807 0.0045% | $13.69 | $79,485 | +8.18% | ||
| 2024-08-22 | Sale | Chief Executive Officer | 6,749 0.0057% | $22.53 | $152,053 | -26.88% | ||
| 2024-08-22 | Sale | See Remarks | 4,351 0.0037% | $22.53 | $98,027 | -26.88% | ||
| 2024-08-22 | Sale | Former Chief Financial Officer | 2,961 0.0025% | $22.53 | $66,710 | -26.88% | ||
| 2024-05-22 | Sale | Chief Executive Officer | 4,877 0.0041% | $24.30 | $118,529 | -17.64% | ||
| 2024-05-22 | Sale | See Remarks | 4,087 0.0034% | $24.30 | $99,329 | -17.64% | ||
| 2024-05-22 | Sale | Chief Financial Officer | 2,936 0.0025% | $24.30 | $71,355 | -17.64% | ||
| 2024-03-04 | Sale | Chief Executive Officer | 4,660 0.0038% | $44.00 | $205,021 | -50.47% | ||
| 2024-02-22 | Sale | Chief Executive Officer | 2,821 0.0028% | $46.34 | $130,737 | -51.16% | ||
| 2024-02-22 | Sale | See Remarks | 2,613 0.0026% | $46.34 | $121,098 | -51.16% | ||
| 2024-02-22 | Sale | Chief Financial Officer | 1,865 0.0018% | $46.34 | $86,432 | -51.16% | ||
| 2024-02-15 | Sale | Chief Executive Officer | 5,000 0.0043% | $48.87 | $244,332 | -53.46% | ||
| 2024-02-09 | Sale | Chief Executive Officer | 1,000 0.001% | $49.53 | $49,530 | -54.76% | ||
| 2024-01-16 | Sale | Chief Executive Officer | 4,000 0.0034% | $45.24 | $180,956 | -49.10% | ||
| 2023-12-14 | Sale | Chief Executive Officer | 2,000 0.0017% | $55.03 | $110,065 | -56.85% | ||
| 2023-11-24 | Sale | Chief Executive Officer | 3,723 0.0032% | $43.72 | $162,751 | -37.86% | ||
| 2023-11-22 | Sale | Chief Executive Officer | 3,757 0.0032% | $43.34 | $162,816 | -37.74% | ||
| 2023-11-22 | Sale | See Remarks | 3,449 0.0029% | $43.34 | $149,468 | -37.74% | ||
| 2023-11-22 | Sale | Chief Financial Officer | 1,679 0.0014% | $43.34 | $72,762 | -37.74% |
Insider Historical Profitability
| McAnear Justin J. | Former Chief Financial Officer | 143242 0.1183% | $14.04 | 1 | 38 | <0.0001% |
| Foresite Capital Management I, LLC | 10 percent owner | 2350000 1.9413% | $14.04 | 1 | 2 | +46.56% |
| ROBERTS BRYAN E | director | 1287825 1.0638% | $14.04 | 1 | 1 | +41.14% |
| CRUTCHFIELD BRADFORD | Chief Commercial Officer | 97237 0.0803% | $14.04 | 1 | 31 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $485.23M | 10.8 | 12.93M | +1.12% | +$5.39M | 0.03 | |
| The Vanguard Group | $341.58M | 7.6 | 9.1M | +1% | +$3.39M | 0.01 | |
| Baillie Gifford Co | $278.65M | 6.2 | 7.42M | -6.25% | -$18.59M | 0.22 | |
| ARK Investment Management LLC | $235.83M | 5.25 | 6.28M | +55.49% | +$84.16M | 0.82 | |
| BlackRock | $225.47M | 5.02 | 6.01M | +5.3% | +$11.34M | 0.01 |